Alyeska Investment Group
AKRO

Alyeska Investment Group’s Akero Therapeutics AKRO Stock Holding History

Alyeska Investment Group’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-64,688
Closed -$1.24M – 399
2019
Q2 		$1.24M Buy
+64,688
New +$1.23M 0.02% 356

Other funds holding AKRO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group's AKRO Position: Q3 2019 in Review

Alyeska Investment Group sold out of Akero Therapeutics (AKRO) in Q3 2019, closing a stake of 64,688 shares — an estimated $1.24M sold.

Alyeska Investment Group first reported a position in AKRO in Q2 2019 and held it in 1 quarter. The position peaked at $1.24M in Q2 2019. 54 funds tracked by Wall St. Rank hold AKRO as of Q3 2019.

  • Alyeska Investment Group reported no remaining Akero Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Alyeska Investment Group sold 64,688 Akero Therapeutics shares in Q3 2019, an estimated $1.24M.
  • Alyeska Investment Group first reported a position in Akero Therapeutics in Q2 2019 and held it in 1 quarter.
  • Alyeska Investment Group's Akero Therapeutics position peaked at $1.24M in Q2 2019.
  • 54 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2019.

Based on Alyeska Investment Group's 13F filing for Q3 2019, filed 14 Nov 2019.